glp-1 receptor agonists and sglt2 inhibitors vs. to Treat the Heart, the Kidneys the Brain Complementary Yet Distinct Roles of

Beyond these frontrunners, the pipeline is expanding: Novo Nordisk filed for FDA approval of CagriSema in 2025, the first once-weekly combination of GLP1 and amylin analogue

If youve heard about GLP-1 medications like Wegovy, Zepbound,or Saxenda, you know they help people lose weight by reducing appetite and slowing digestion

Some even suggest that GLP-1 agonists might have the potential to supplant MASH therapy in its entirety

But from 2030, Pfizer could emerge as a credible Top-3 obesity player if both the injectable and oral combo strategies succeed

Prescription treatment requires review by a licensed clinician, and eligibility, medication selection, and dosing are determined solely by the clinician